Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 12/20 | 0.49 |
| ▸ | FCER2 | P06734 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 14/20 | 0.46 |
| ▸ | MMP3 | P08254 | 8/20 | 0.46 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | MMP7 | P09237 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29024434 | 0.85 | MME (0.49) | MMP2MMP9 | |
| SCHEMBL27349758 | 0.83 | ATM (0.53) | — | |
| SCHEMBL6846291 | 0.78 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7439020 | 0.78 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL4428864 | 0.78 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL4428861 | 0.78 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7439018 | 0.78 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7762294 | 0.75 | MMP1 (0.56) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL21988101 | 0.75 | MMP1 (0.63) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7762297 | 0.75 | MMP1 (0.56) | MMP1FCER2MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133337-A1 | CALICHEAMICIN CONSTRUCTS AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133337-A1 | CALICHEAMICIN CONSTRUCTS AND METHODS OF USE | CALD1, CALR, CLSPN | MMP1 1721/4885FCER2 261/4885MMP2 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.